The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.

Inclusion Criteria:

• Pregnant woman over 18 years old
• Woman whose gestational age is less than 30 weeks.
• Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
• Give birth in the inclusion center
• Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status
• Affiliated with the Social Security system

Exclusion Criteria:

• Patient who underwent a blood transfusion less than 2 months ago
• Patient who received an organ transplant
• Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion